Home / Publication / Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-nucleoside Analog Inhibitor

論文

Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-nucleoside Analog Inhibitor

Author(s): Narita Mallalieu, Mohamad Rahimy, Constance Crowley, James Appleman, Patrick Smith, James Freddo

Year: 2014年12月1日

How Model-informed drug development rescue projects from a risky situation

事例紹介

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

ウェビナー

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

ウェビナー

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

論文

Powered by Translations.com GlobalLink Web Software

Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-nucleoside Analog Inhibitor

Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-nucleoside Analog Inhibitor

How Model-informed drug development rescue projects from a risky situation

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

メルマガ登録

クイックアクセス

ソリューション

お問合せ

Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-nucleoside Analog Inhibitor

How Model-informed drug development rescue projects from a risky situation​

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

メルマガ登録

クイックアクセス

ソリューション

お問合せ

How Model-informed drug development rescue projects from a risky situation